

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

SET-2

RRID:CVCL_2187

Type: Cell Line

Proper Citation

RRID:CVCL_2187

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2187

Proper Citation: RRID:CVCL_2187

Description: Cell line SET-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Adult acute megakaryoblastic leukemia

Defining Citation: [PMID:10637490](#), [PMID:16408098](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31739141](#)

Comments: Population: Japanese., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SET-2

Synonyms: Set-2, Set2, SET2

Cross References: BTO:BTO_0004766, EFO:EFO_0006486, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:804, BioSample:SAMN03473274, BioSample:SAMN10988088, cancercellines:CVCL_2187, Cell_Model_Passport:SIDM00397, ChEMBL-Cells:ChEMBL4523535, ChEMBL-Targets:ChEMBL4523566, Cosmic:1012054, Cosmic:1519162, Cosmic:1633513, Cosmic:1943610, Cosmic:2306995, Cosmic-CLP:1659820, DepMap:ACH-000195,

DSMZ:ACC-608, DSMZCellDive:ACC-608, EGA:EGAS00001000610, EGA:EGAS00001002554, GDSC:1659820, GEO:GSM887564, GEO:GSM888647, GEO:GSM1374868, GEO:GSM1446764, IARC_TP53:28307, LiGeA:CCL_845, Lanza:1318, PharmacDB:Set2_1364_2019, Progenetix:CVCL_2187, PubChem_Cell_line:CVCL_2187, Wikidata:Q54952857

ID: CVCL_2187

Record Creation Time: 20220427T221537+0000

Record Last Update: 20260905T182342+0000

Ratings and Alerts

No rating or validation information has been found for SET-2.

No alerts have been found for SET-2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. *Cell*, 189(1), 215.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. *Cancer discovery*.

Wen J, et al. (2026) Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms. *Cancer cell*.

Le BV, et al. (2026) Pol γ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. *Cell reports. Medicine*, 7(3), 102687.

Fiskus W, et al. (2025) Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. *Blood advances*, 9(21), 5598.

Fiskus W, et al. (2025) Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. *Blood*, 145(6), 612.

Guillen Magaña JN, et al. (2025) Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. *Cancer research communications*, 5(11), 2012.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. *Cancer discovery*.

Cai W, et al. (2024) Augmenting CAR T-cell Functions with LIGHT. *Cancer immunology research*, 12(10), 1361.

Kansy AG, et al. (2024) Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells. *Molecular oncology*, 18(8), 1958.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. *Cell reports. Medicine*, 5(6), 101592.

Ben-Crentsil NA, et al. (2024) RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. *Cancer discovery*, 14(12), 2509.

Pritchard JE, et al. (2024) Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. *Cell reports*, 43(1), 113608.

Arwood ML, et al. (2023) New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. *Cell chemical biology*, 30(6), 618.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 943.

Saleiro D, et al. (2023) Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. *Cancer research communications*, 3(5), 943.

Radziskeuskaya A, et al. (2023) An alternative NURF complex sustains acute myeloid leukemia by regulating the accessibility of insulator regions. *The EMBO journal*, 42(24), e114221.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. *Cell reports*, 38(2), 110233.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. *Cancer cell*, 40(3), 301.

Hernández-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.